Nonhuman primates and other animal models in diabetes research

Journal of Diabetes Science and Technology

Volumn 6, Issue 3, 2012, Pages 503-514

  Harwood Jr , H James ^a   Listrani, Paul ^a   Wagner, Janice D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Diabetes; Metabolic syndrome; Nonhuman primates; Obesity; Therapeutic intervention

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SEX HORMONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADRENAL CORTEX HYPERFUNCTION; ANIMAL MODEL; CALLITHRIX; CALLITRICHINAE; CAT; CEBUS; CEBUS APELLA; CELL PROLIFERATION; CHIMPANZEE; CLINICAL FEATURE; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FOLLICULAR PHASE; GLYCEMIC CONTROL; HEPATOMEGALY; HISTOPATHOLOGY; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIVER CELL CARCINOMA; LUTEAL PHASE; MACACA; MANDRILLUS; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET; PANCREAS ISLET CELL HYPERPLASIA; PERIPHERAL NEUROPATHY; PRIMATE; PROTEIN GLYCOSYLATION; RHESUS MONKEY; RODENT; SAIMIRI SCIUREUS; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WHITE ADIPOSE TISSUE; ANIMAL; BLOOD; DISEASE COURSE; DISEASE MODEL; DOG; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SPECIES DIFFERENCE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PRIMATES; PROGNOSIS; RISK FACTORS; SPECIES SPECIFICITY;

EID: 84879701205     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600304     Document Type: Conference Paper

References (175)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53. (Pubitemid 38579764)
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35 Suppl 1:S64-71.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
4. Harwood HJ Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets. 2005;9(2):267-81.
5. Centers for Disease Control and Prevention. National health and nutrition examination survey. http://www.cdc.gov/nchs/nhanes.htm.
6. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb. 1992;12(6):647-56.
7. Cefalu WT. Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition. ILAR J. 2006;47(3):186-98. (Pubitemid 43986028)
8. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787-94. (Pubitemid 29536364)
9. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427-36. (Pubitemid 36241019)
10. DeFronzo RA. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5(3):177-269. (Pubitemid 27453244)
11. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035-8. (Pubitemid 9228506)
12. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41(6):715-22.
13. Pennathur S, Heinecke JW. Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Front Biosci. 2004;9:565-74. (Pubitemid 39043735)
14. Rowe PA, Kavanagh K, Zhang L, Harwood HJ Jr, Wagner JD. Short-term hyperglycemia increases arterial superoxide production and iron dysregulation in atherosclerotic monkeys. Metabolism. 2011;60(8):1070-80.
15. Brownlee M. The pathogenesis of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-25. (Pubitemid 40770750)
16. Kaneko JJ. Carbohydrate metabolism. In: Loeb WF, Quimby FW, eds. The clinical chemistry of laboratory animals. 2nd ed. Philadelphia: Taylor and Francis; 1999.
17. Hoenig M, Thomaseth K, Waldron M, Ferguson DC. Insulin sensitivity, fat distribution, and adipocytokine response to diferent diets in lean and obese cats before and after weight loss. Am J Physiol Regul Integr Comp Physiol. 2007;292(1):R227-34. (Pubitemid 46089834)
18. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100(5):1166-73.
19. Henson MS, O'Brien TD. Feline models of type 2 diabetes mellitus. ILAR J. 2006;47(3):234-42. (Pubitemid 43986032)
20. Johnson KH, Hayden DW, O'Brien TD, Westermark P. Spontaneous diabetes mellitus-islet amyloid complex in adult cats. Am J Pathol. 1986;125(2):416-9. (Pubitemid 17194699)
21. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med. 1989;321(8):513-8. (Pubitemid 19203876)
22. O'Brien TD, Hayden DW, Johnson KH, Stevens JB. High dose intravenous glucose tolerance test and serum insulin and glucagon levels in diabetic and non-diabetic cats: Relationships to insular amyloidosis. Vet Pathol. 1985;22(3):250-61.
23. O'Brien TD, Hayden DW, Johnson KH, Fletcher TF. Immunohistochemical morphometry of pancreatic endocrine cells in diabetic, normoglycaemic glucose-intolerant and normal cats. J Comp Pathol. 1986;96(4):357-69. (Pubitemid 16066157)
24. O'Brien TD, Butler PC, Westermark P, Johnson KH. Islet amyloid polypeptide: A review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet Pathol. 1993;30(4):317-32.
25. O'Brien TD, Wagner JD, Litwak KN, Carlson CS, Cefalu WT, Jordan K, Johnson KH, Butler PC. Islet amyloid and islet amyloid polypeptide in cynomolgus macaques (Macaca fascicularis): an animal model of human non-insulin-dependent diabetes mellitus. Vet Pathol. 1996;33(5):479-85. (Pubitemid 126479727)
26. Hoenig M. Comparative aspects of diabetes mellitus in dogs and cats. Mol Cell Endocrinol. 2002;197(1-2):221-9. (Pubitemid 35304796)
27. Marmor M, Willeberg P, Glickman LT, Priester WA, Cypess RH, Hurvitz AI. Epizootiologic patterns of diabetes mellitus in dogs. Am J Vet Res. 1982;43(3):465-70.
28. Verkest KR, Rand JS, Fleeman LM, Morton JM. Spontaneously obese dogs exhibit greater postprandial glucose, triglyceride, and insulin concentrations than lean dogs. Domest Anim Endocrinol. 2012;42(2):103-12.
29. Ionut V, Liu H, Mooradian V, Castro AV, Kabir M, Stefanovski D, Zheng D, Kirkman EL, Bergman RN. Novel canine models of obese prediabetes and mild type 2 diabetes. Am J Physiol Endocrinol Metab. 2010;298(1):E38-48.
30. Bellinger DA, Merricks EP, Nichols TC. Swine models of type 2 diabetes mellitus: Insulin resistance, glucose tolerance, and cardiovascular complications. ILAR J. 2006;47(3):243-58. (Pubitemid 43986033)
31. Prentice AM, Rayco-Solon P, Moore SE. Insights from the developing world: Thrifty genotypes and thrifty phenotypes. Proc Nutr Soc. 2005;64(2):153-61. (Pubitemid 40813537)
32. Phillips RW, Panepinto LM, Spangler R, Westmoreland N. Yucatan miniature swine as a model for the study of human diabetes mellitus. Diabetes. 1982;31(Suppl 1 Pt 2):30-6. (Pubitemid 12128683)
33. Phillips RW, Panepinto LM. Swine as a model for human diabetes. In: Swine in biomedical research. Vol. 1. New York: Plenum Press; 1986.
34. Gerrity RG, Naito HK, Richardson M, Schwartz CJ. Dietary induced atherogenesis in swine. Morphology of the intima in prelesion stages. Am J Pathol. 1979;95(3):775-92. (Pubitemid 9182867)
35. Prescott MF, Hasler-Rapacz J, von Linden-Reed J, Rapacz J. Familial hypercholesterolemia associated with coronary atherosclerosis in swine bearing diferent alleles for apolipoprotein B. Ann N Y Acad Sci. 1995;748:283-93.
36. Prescott MF, McBride CH, Hasler-Rapacz J, Von Linden J, Rapacz J. Development of complex atherosclerotic lesions in pigs with inherited hyper-LDL cholesterolemia bearing mutant alleles for apolipoprotein B. Am J Pathol. 1991;139(1):139-47.
37. Wagner JD, Kavanagh K, Ward GM, Auerbach BJ, Harwood HJ Jr, Kaplan JR. Old world nonhuman primate models of type 2 diabetes mellitus. ILAR J. 2006;47(3):259-71. (Pubitemid 43986034)
38. Wagner JD, Cann JA, Zhang L, Harwood HJ Jr. Diabetes and obesity research using nonhuman primates. In: Abee CR, Mansfield K, Tardif SD, Morris T, eds. Nonhuman primates in biomedical research Volume 2: Diseases. 2nd ed. 2012. Elsevier. Chapter 14, pp 699-732.
39. Kavanagh K, Fairbanks LA, Bailey JN, Jorgensen MJ, Wilson M, Zhang L, Rudel LL, Wagner JD. Characterization and heritability of obesity and associated risk factors in vervet monkeys. Obesity (Silver Spring). 2007;15(7):1666-74. (Pubitemid 47264945)
40. Cann JA, Kavanagh K, Jorgensen MJ, Mohanan S, Howard TD, Gray SB, Hawkins GA, Fairbanks LA, Wagner JD. Clinicopathologic characterization of naturally occurring diabetes mellitus in vervet monkeys. Vet Pathol. 2010;47(4):713-8.
41. Stokes WS. Spontaneous diabetes mellitus in a baboon (Papio cynocephalus anubis). Lab Anim Sci. 1986;36(5):529-33.
42. Cai G, Cole SA, Tejero ME, Profitt JM, Freeland-Graves JH, Blangero J, Comuzzie AG. Pleiotropic efects of genes for insulin resistance on adiposity in baboons. Obes Res. 2004;12(11):1766-72. (Pubitemid 41133025)
43. Tejero ME, Voruganti VS, Rodríguez-Sánchez IP, Proffitt JM, Blangero J, Cox LA, Mahaney MC, Rogers J, VandeBerg JL, Cole SA, Comuzzie AG. Genetics of variation in adiponectin in pedigreed baboons: evidence for pleiotropic efects on adipocyte volume and serum adiponectin. Heredity (Edinb). 2008;100(4):382-9. (Pubitemid 351441860)
44. Comuzzie AG, Cole SA, Martin L, Carey KD, Mahaney MC, Blangero J, VandeBerg JL. The baboon as a nonhuman primate model for the study of the genetics of obesity. Obes Res. 2003;11(1):75-80. (Pubitemid 41137541)
45. Pirarat N, Kesdangsakolwut S, Chotiapisitkul S, Assarasakorn S. Spontaneous diabetes mellitus in captive Mandrillus sphinx monkeys: a case report. J Med Primatol. 2008;37(3):162-5. (Pubitemid 351803091)
46. Abbott DH, Foong SC, Barnett DK, Dumesic DA. Nonhuman primates contribute unique understanding to anovulatory infertility in women. ILAR J. 2004;45(2):116-31.
47. Tardif SD, Power ML, Ross CN, Rutherford JN, Layne-Colon DG, Paulik MA. Characterization of obese phenotypes in a small nonhuman primate, the common marmoset (callithrix jacchus). Obesity (Silver Spring). 2009;17(8):1499-505.
48. Tardif SD, Mansfield KG, Ratnam R, Ross CN, Ziegler TE. The marmoset as a model of aging and age-related diseases. ILAR J. 2011;52(1):54-65.
49. Bodkin NL. The rhesus monkey (Macaca mulatta):a unique and valuable model for the study of spontaneous diabetes mellitus and associated conditions. In: Sima AF, Shafrir E, eds. Animal models in diabetes: a primer. Singapore: Taylor & Francis; 2000.
50. Clarkson TB, Koritnik DR, Weingand KW, Miller LC. Nonhuman primate models of atherosclerosis: Potential for the study of diabetes mellitus and hyperinsulinemia. Metabolism. 1985;34(12 Suppl 1):51-9. (Pubitemid 16105237)
51. Rosenblum IY, Barbolt TA, Howard CF Jr. Diabetes mellitus in the chimpanzee (Pan troglodytes). J Med Primatol. 1981;10(2-3):93-101. (Pubitemid 12249383)
52. McTighe MS, Hansen BC, Ely JJ, Lee DR. Determination of hemoglobin A1c and fasting blood glucose reference intervals in captive chimpanzees (Pan troglodytes). J Am Assoc Lab Anim Sci. 2011;50(2):165-70.
53. Howard CF Jr, Yasuda M. Diabetes mellitus in nonhuman primates: Recent research advances and current husbandry practices. J Med Primatol. 1990;19(7):609-25. (Pubitemid 20386433)
54. Hamilton CL, Ciaccia P. The course of development of glucose intolerance in the monkey (Macaca mulatta). J Med Primatol. 1978;7(3):165-73. (Pubitemid 9010878)
55. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001;50(5):1126-33. (Pubitemid 32374544)
56. Wagner JD, Carlson CS, O'Brien TD, Anthony MS, Bullock BC, Cefalu WT. Diabetes mellitus and islet amyloidosis in cynomolgus monkeys. Lab Anim Sci. 1996;46(1):36-41.
57. Banks WA, Altmann J, Sapolsky RM, Phillips-Conroy JE, Morley JE. Serum leptin levels as a marker for a syndrome X-like condition in wild baboons. J Clin Endocrinol Metab. 2003;88(3):1234-40. (Pubitemid 36337783)
58. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: Phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia. 1986;29(10):713-9. (Pubitemid 17051041)
59. Wagner JD, Cline JM, Shadoan MK, Bullock BC, Rankin SE, Cefalu WT. Naturally occurring and experimental diabetes in cynomolgus monkeys: A comparison of carbohydrate and lipid metabolism and islet pathology. Toxicol Pathol. 2001;29(1):142-8. (Pubitemid 32127333)
60. Wagner JD, Jayo MJ, Bullock BC, Washburn SA. Gestational diabetes mellitus in a cynomolgus monkey with group A streptococcal metritis and hemolytic uremic syndrome. J Med Primatol. 1992;21(7-8):371-4.
61. Kessler MJ, Howard CF Jr, London WT. Gestational diabetes mellitus and impaired glucose tolerance in an aged Macaca mulatta. J Med Primatol. 1985;14(5):237-44. (Pubitemid 16243849)
62. Bauer SA, Arndt TP, Leslie KE, Pearl DL, Turner PV. Obesity in rhesus and cynomolgus macaques: a comparative review of the condition and its implications for research. Comp Med. 2011;61(6):514-26.
63. Howard CF Jr. Diabetes in Macaca nigra: metabolic and histologic changes. Diabetologia. 1974;10 Suppl:671-7.
64. Howard CF. Atherosclerosis and insulin in primates with diabetes mellitus. Metabolism. 1985;34(12 Suppl 1):60-6.
65. Riley WJ, Maclaren NK. Islet cell autoantibodies. In: Samols E, ed. The endocrine pancreas. New York: Raven Press; 1991.
66. Kaufman D, Smith EL, Gohil BC, Banerji M, Coplan JD, Kral JG, Rosenblum LA. Early appearance of the metabolic syndrome in socially reared bonnet macaques. J Clin Endocrinol Metab. 2005;90(1):404-8. (Pubitemid 40116688)
67. Kaufman D, Banerji MA, Shorman I, Smith EL, Coplan JD, Rosenblum LA, Kral JG. Early-life stress and the development of obesity and insulin resistance in juvenile bonnet macaques. Diabetes. 2007;56(5):1382-6. (Pubitemid 46715631)
68. Tanaka Y, Ohto H, Kohno M, Cho F, Honjo S. Spontaneous diabetes mellitus in cynomolgus monkeys (macaca fascicularis). Jikken Dobutsu. 1986;35(1):11-9.
69. Yasuda M, Takaoka M, Fujiwara T, Mori M. Occurrence of spontaneous diabetes mellitus in a cynomolgus monkey (Macaca fascicularis) and impaired glucose tolerance in its descendants. J Med Primatol. 1988;17(6):319-32. (Pubitemid 19059033)
70. Bagdade JD, Wagner JD, Rudel LL, Clarkson TB. Accelerated cholesteryl ester transfer and altered lipoprotein composition in diabetic cynomolgus monkeys. J Lipid Res. 1995;36(4):759-66.
71. Hansen BC, Bodkin NL. Beta-cell hyperresponsiveness: Earliest event in development of diabetes in monkeys. Am J Physiol. 1990;259(3 Pt 2):R612-7. (Pubitemid 20307586)
72. De Koning EJ, Bodkin NL, Hansen BC, Clark A. Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia. 1993;36(5):378-84. (Pubitemid 23124039)
73. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia. 2004;47(2):157-69. (Pubitemid 38315352)
74. Ramsey JJ, Laatsch JL, Kemnitz JW. Age and gender diferences in body composition, energy expenditure, and glucoregulation of adult rhesus monkeys. J Med Primatol. 2000;29(1):11-9. (Pubitemid 30339604)
75. Tigno XT, Gerzanich G, Hansen BC. Age-related changes in metabolic parameters of nonhuman primates. J Gerontol A Biol Sci Med Sci. 2004;59(11):1081-8. (Pubitemid 40024272)
76. Kemnitz JW, Francken GA. Characteristics of spontaneous obesity in male rhesus monkeys. Physiol Behav. 1986;38(4):477-83.
77. Howard CF Jr, Kessler MJ, Schwartz S. Carbohydrate impairment and insulin secretory abnormalities among Macaca mulatta from Cayo Santiago. Am J Primatol. 1986;11(2):147-62.
78. Kemnitz JW, Gibber JR, Lindsay KA, Eisele SG. Efects of ovarian hormones on eating behaviors, body weight, and glucoregulation in rhesus monkeys. Horm Behav. 1989;23(2):235-50. (Pubitemid 19147105)
79. Skyler JS, O'Sullivan MJ, Holsinger KK. The relationship between maternal glycemia and macrosomia. Diabetes Care. 1980;3(3):433-4. (Pubitemid 10000689)
80. Litwak KN, Cefalu WT, Wagner JD. Streptozotocin-induced diabetes mellitus in cynomolgus monkeys: Changes in carbohydrate metabolism, skin glycation, and pancreatic islets. Lab Anim Sci. 1998;48(2):172-8.
81. Contreras JL, Smyth CA, Curiel DT, Eckhof DE. Nonhuman primate models in type 1 diabetes research. ILAR J. 2004;45(3):334-42. (Pubitemid 351858404)
82. Gaur LK, Nepom GT, Lernmark A. Low-dose streptozotocin induces sustained hyperglycemia in Macaca nemestrina. Autoimmunity. 2001;33(2):103-14. (Pubitemid 32293978)
83. V on Herrath M, Nepom GT. Animal models of human type 1 diabetes. Nat Immunol. 2009;10(2):129-32.
84. Saisho Y, Butler AE, Manesso E, Galasso R, Zhang L, Gurlo T, Tofolo GM, Cobelli C, Kavanagh K, Wagner JD, Butler PC. Relationship between fractional pancreatic beta cell area and fasting plasma glucose concentration in monkeys. Diabetologia. 2010;53(1):111-4.
85. Kavanagh K, Jones KL, Sawyer J, Kelley K, Carr JJ, Wagner JD, Rudel LL. Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity (Silver Spring). 2007;15(7):1675-84. (Pubitemid 47264946)
86. Litwak KN, Cefalu WT, Wagner JD. Chronic hyperglycemia increases arterial low-density lipoprotein metabolism and atherosclerosis in cynomolgus monkeys. Metabolism. 1998;47(8):947-54. (Pubitemid 28364612)
87. Cefalu WT, Wagner JD. Aging and atherosclerosis in human and nonhuman primates. Age. 1997;20:15-28.
88. Higgins PB, Bastarrachea RA, Lopez-Alvarenga JC, Garcia-Forey M, Profitt JM, Voruganti VS, Tejero ME, Mattern V, Haack K, Shade RE, Cole SA, Comuzzie AG. Eight week exposure to a high sugar high fat diet results in adiposity gain and alterations in metabolic biomarkers in baboons (Papio hamadryas sp.). Cardiovasc Diabetol. 2010;9:71.
89. Wachtman LM, Kramer JA, Miller AD, Hachey AM, Curran EH, Mansfield KG. Diferential contribution of dietary fat and monosaccharide to metabolic syndrome in the common marmoset (Callithrix jacchus). Obesity (Silver Spring). 2011;19(6):1145-56.
90. Wagner JD. Effects of ERT and HRT on cardiovascular risk factors and coronary artery atherosclerosis. Menopausal Med. 2001;10:12-5.
91. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A. 2006;103(7):2334-9. (Pubitemid 43271670)
92. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293-300.
93. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004;89(8):3629-43. (Pubitemid 39071447)
94. Cromeens DM, Stephens LC. Insular amyloidosis and diabetes mellitus in a crab-eating macaque (Macaca fascicularis). Lab Anim Sci. 1985;35(6):642-5. (Pubitemid 16184880)
95. Howard CF Jr, Van Bueren A. Changes in islet cell composition during development of diabetes in Macaca nigra. Diabetes. 1986;35(2):165-71. (Pubitemid 16121533)
96. Hubbard GB, Steele KE, Davis KJ 3rd, Leland MM. Spontaneous pancreatic islet amyloidosis in 40 baboons. J Med Primatol. 2002;31(2):84-90. (Pubitemid 34520646)
97. Ohagi S, Nishi M, Bell GI, Ensinck JW, Steiner DF. Sequences of islet amyloid polypeptide precursors of an Old World monkey, the pig-tailed macaque (Macaca nemestrina), and the dog (Canis familiaris). Diabetologia. 1991;34(8):555-8.
98. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233-40. (Pubitemid 29056916)
99. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet. 2006;368(9548):1651-9. (Pubitemid 46048553)
100. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-8. (Pubitemid 40923403)
101. Matrougui K. Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase. Diabetes Metab Res Rev. 2010;26(1):13-6.
102. Brown WV. Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. Am J Cardiol. 2008;102(12A):10L-13L.
103. Cusumano AM, Bodkin NL, Hansen BC, Iotti R, Owens J, Klotman PE, Kopp JB. Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis. 2002;40(5):1075-85. (Pubitemid 35265489)
104. Johnson MA, Lutty GA, McLeod DS, Otsuji T, Flower RW, Sandagar G, Alexander T, Steidl SM, Hansen BC. Ocular structure and function in an aged monkey with spontaneous diabetes mellitus. Exp Eye Res. 2005;80(1):37-42. (Pubitemid 40126512)
105. Kim SY, Johnson MA, McLeod DS, Alexander T, Hansen BC, Lutty GA. Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas. Diabetes. 2005;54(5):1534-42. (Pubitemid 40586687)
106. Bruns CM, Kemnitz JW. Sex hormones, insulin sensitivity, and diabetes mellitus. ILAR J. 2004;45(2):160-9.
107. Kemnitz JW, Holston KA, Colman RJ. Nutrition, aging and reproduction in rhesus monkeys. In: Hansel W, Bray GA, Ryan DH, eds. Pennington center nutrition series. Part IV. Evolution of research methods in nutrition and reproduction. Nutrition and reproduction Vol. 8. Baton Rouge: Louisiana State University Press; 1998.
108. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Hafner SM, Saad MF, Bergman RN. Insulin sensitivity, insulin secretion, and abdominal fat: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003;52(10):2490-6. (Pubitemid 37210536)
109. Arifin E, Shively CA, Register TC, Cline JM. Polycystic ovary syndrome with endometrial hyperplasia in a cynomolgus monkey (Macaca fascicularis). Vet Pathol. 2008;45(4):512-5.
110. Fujisawa S, Atsumi T, Kadoma Y. Metabolic abnormalities among free-ranging Macaca mulatta on Cayo Santiago: comparisons with Macaca mulatta at Sabana Seca. Am J Primatol. 1990;21(3):189-200.
111. Weinbauer GF, Niehof M, Niehaus M, Srivastav S, Fuchs A, Van Esch E, Cline JM. Physiology and endocrinology of the ovarian cycle in macaques. Toxicol Pathol. 2008;36(7S):7S-23S.
112. Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab. 1991;72(3):642-6. (Pubitemid 21921742)
113. Chen LD, Kushwaha RS, McGill HC Jr, Rice KS, Carey KD. Efect of naturally reduced ovarian function on plasma lipoprotein and 27-hydroxycholesterol levels in baboons (Papio sp.). Atherosclerosis. 1998;136(1):89-98. (Pubitemid 28341445)
114. Gilardi KV, Shideler SE, Valverde CR, Roberts JA, Lasley BL. Characterization of the onset of menopause in the rhesus macaque. Biol Reprod. 1997;57(2):335-40. (Pubitemid 27343692)
115. Gould KG, Flint M, Graham CE. Chimpanzee reproductive senescence: A possible model for evolution of the menopause. Maturitas. 1981;3(2):157-66. (Pubitemid 11021570)
116. Kavanagh K, Koudy Williams J, Wagner JD. Naturally occurring menopause in cynomolgus monkeys: Changes in hormone, lipid, and carbohydrate measures with hormonal status. J Med Primatol. 2005;34(4):171-7. (Pubitemid 40932216)
117. Lindheim SR, Buchanan TA, Dufy DM, Vijod MA, Kojima T, Stanczyk FZ, Lobo RA. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Investig. 1994;1(2):150-4. (Pubitemid 2107006)
118. Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT. The efects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism. 1996;45(10):1254-62. (Pubitemid 26337672)
119. Wagner JD, Cefalu WT, Anthony MS, Litwak KN, Zhang L, Clarkson TB. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism. 1997;46(6):698-705. (Pubitemid 27247307)
120. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr. 1992;55(5):950-4.
121. Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 1991;40(12):1323-6.
122. .Matute ML, Kalkhof RK. Sex steroid influence on hepatic gluconeogenesis and glycogen formation. J Lab Clin Med. 1971;78(6):997-8.
123. Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, Surmacz E, Andò S. Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells. Biochem Biophys Res Commun. 2001;288(3):685-9. (Pubitemid 33030084)
124. Wagner JD, Kaplan JR, Burkman RT. Reproductive hormones and cardiovascular disease mechanism of action and clinical implications. Obstet Gynecol Clin North Am. 2002;29(3):475-93.
125. Björntorp P. Neuroendocrine perturbations as a cause of insulin resistance. Diabetes Metab Res Rev. 1999;15(6):427-41.
126. Rosmond R. Stress induced disturbances of the HPA axis: a pathway to type 2 diabetes? Med Sci Monit. 2003;9(2):RA35-9. (Pubitemid 36330375)
127. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord. 2000;24 Suppl 2:S50-5. (Pubitemid 30461948)
128. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med. 2004;66(3):316-22. (Pubitemid 38668398)
129. Kaplan JR. Dominance and afiliation in the Cercopithecini and Papionini: a comparative examination. Monogr Primatol. 1987;10:127-50.
130. Kaplan JR, Manuck SB. Status, stress, and atherosclerosis: the role of environment and individual behavior. Ann N Y Acad Sci. 1999;896:145-61. (Pubitemid 30040245)
131. Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E, Hansen BC. Mortality and morbidity in laboratory-maintained rhesus monkeys and efects of long-term dietary restriction. J Gerontol A Biol Sci Med Sci. 2003;58(3):212-9. (Pubitemid 36307591)
132. Cefalu WT, Wang ZQ, Bell-Farrow AD, Collins J, Morgan T, Wagner JD. Caloric restriction and cardiovascular aging in cynomolgus monkeys (Macaca fascicularis): metabolic, physiologic, and atherosclerotic measures from a 4-year intervention trial. J Gerontol A Biol Sci Med Sci. 2004;59(10):1007-14. (Pubitemid 39441789)
133. Gresl TA, Colman RJ, Roecker EB, Havighurst TC, Huang Z, Allison DB, Bergman RN, Kemnitz JW. Dietary restriction and glucose regulation in aging rhesus monkeys: a follow-up report at 8.5 yr. Am J Physiol Endocrinol Metab. 2001;281(4):E757-65.
134. Hansen BC, Bodkin NL, Ortmeyer HK. Calorie restriction in nonhuman primates: Mechanisms of reduced morbidity and mortality. Toxicol Sci. 1999;52(2 Suppl):56-60. (Pubitemid 30017576)
135. Wagner JD, Bagdade JD, Litwak KN, Zhang L, Bell-Farrow AD, Wang ZQ, Cefalu WT. Increased glycation of plasma lipoproteins in diabetic cynomolgus monkeys. Lab Anim Sci. 1996;46(1):31-5.
136. Bodkin NL, Ortmeyer HK, Hansen BC. Long-term dietary restriction in older-aged rhesus monkeys: efects on insulin resistance. J Gerontol A Biol Sci Med Sci. 1995;50(3):B142-7.
137. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes. 1994;43(2):204-11.
138. Lane MA, Black A, Handy A, Tilmont EM, Ingram DK, Roth GS. Caloric restriction in primates. Ann N Y Acad Sci. 2001;928:287-95. (Pubitemid 32386090)
139. Wang ZQ, Floyd ZE, Qin J, Liu X, Yu Y, Zhang XH, Wagner JD, Cefalu WT. Modulation of skeletal muscle insulin signaling with chronic caloric restriction in cynomolgus monkeys. Diabetes. 2009;58(7):1488-98.
140. Nyirenda MJ, Carter R, Tang JI, de Vries A, Schlumbohm C, Hillier SG, Streit F, Oellerich M, Armstrong VW, Fuchs E, Seckl JR. Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1. Diabetes. 2009;58(12):2873-9.
141. Wagner JD, Jorgensen MJ, Cline JM, Lees CJ, Franke AA, Zhang L, Ayers MR, Schultz C, Kaplan JR. Efects of soy vs. casein protein on body weight and glycemic control in female monkeys and their ofspring. Am J Primatol. 2009;71(9):802-11.
142. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol. 2000;40:491-518. (Pubitemid 30340691)
143. Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WQ, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, Hansen BC. Efects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res. 2001;42(10):1543-51. (Pubitemid 33020086)
144. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43(4):527-50. (Pubitemid 30127149)
145. Harwood HJ Jr, Hamanaka ES. Modulators of dyslipidemia. Emerg Drug. 1998;3:147-72.
146. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr. 2002;22:167-97.
147. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144(6):2201-7. (Pubitemid 36629867)
148. Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice. Curr Opin Lipidol. 2001;12(3):245-54. (Pubitemid 32521948)
149. Goldstein BJ. Rosiglitazone. Int J Clin Pract. 2000;54(5):333-7. (Pubitemid 30386644)
150. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43(3):278-84. (Pubitemid 30163470)
151. Gee MK, Zhang L, Rankin SE, Collins JN, Kaufman RF, Wagner JD. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys. Metabolism. 2004;53(9):1121-5. (Pubitemid 39140744)
152. Kavanagh K, Brown KK, Berquist ML, Zhang L, Wagner JD. Fluid compartmental shifts with eficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes. Metabolism. 2010;59(6):914-20.
153. Kemnitz JW, Roecker EB, Weindruch R, Elson DF, Baum ST, Bergman RN. Dietary restriction increases insulin sensitivity and lowers blood glucose in rhesus monkeys. Am J Physiol. 1994;266(4 Pt 1):E540-7.
154. Ortmeyer HK, Bodkin NL, Haney J, Yoshioka S, Horikoshi H, Hansen BC. A thiazolidinedione improves in vivo insulin action on skeletal muscle glycogen synthase in insulin-resistant monkeys. Int J Exp Diabetes Res. 2000;1(3):195-202.
155. Faergeman O. Hypertriglyceridemia and the fibrate trials. Curr Opin Lipidol. 2000;11(6):609-14.
156. Jones AB. Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Med Res Rev. 2001;21(6):540-52. (Pubitemid 32959242)
157. Castrillo A, Tontonoz P. PPARs in atherosclerosis: the clot thickens. J Clin Invest. 2004;114(11):1538-40. (Pubitemid 40385542)
158. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Diferential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest. 2004;114(11):1564-76. (Pubitemid 40385547)
159. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357(9260):905-10.
160. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21(4):641-8. (Pubitemid 28172949)
161. Wallace JM, Schwarz M, Coward P, Houze J, Sawyer JK, Kelley KL, Chai A, Rudel LL. Efects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res. 2005;46(5):1009-16.
162. Wagner JD, Shadoan MK, Zhang L, Ward GM, Royer LJ, Kavanagh K, Francone OL, Auerbach BJ, Harwood HJ Jr. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J Pharmacol Exp Ther. 2010;333(3):844-53.
163. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, Cowley H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos. 2000;28(7):772-80. (Pubitemid 30470827)
164. Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC. A novel peroxisome proliferator - activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism. 2007;56(10):1334-9. (Pubitemid 47422240)
165. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1):73-100. (Pubitemid 43228239)
166. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes. 2008;57(11):2977-91.
167. Nogueiras R, Diaz-Arteaga A, Lockie SH, Velásquez DA, Tschop J, López M, Cadwell CC, Diéguez C, Tschöp MH. The endocannabinoid system: Role in glucose and energy metabolism. Pharmacol Res. 2009;60(2):93-8.
168. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Bátkai S, Marsicano G, Lutz B, Buettner C, Kunos G. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008;118(9):3160-9.
169. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S. Food intake-independent efects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring). 2009;17(8):1641-5.
170. Quarta C, Bellocchio L, Mancini G, Mazza R, Cervino C, Braulke LJ, Fekete C, Latorre R, Nanni C, Bucci M, Clemens LE, Heldmaier G, Watanabe M, Leste-Lassere T, Maitre M, Tedesco L, Fanelli F, Reuss S, Klaus S, Srivastava RK, Monory K, Valerio A, Grandis A, De Giorgio R, Pasquali R, Nisoli E, Cota D, Lutz B, Marsicano G, Pagotto U. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab. 2010;11(4):273-85.
171. Butler H, Korbonits M. Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol. 2009;161(5):655-62.
172. Akbas F, Gasteyger C, Sjödin A, Astrup A, Larsen TM. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev. 2009;10(1):58-67.
173. Wagner JD, Zhang L, Kavanagh K, Ward GM, Chin JE, Hadcock JR, Auerbach BJ, Harwood HJ Jr. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys. J Pharmacol Exp Ther. 2010;335(1):103-13
174. Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005;48(9):1700-13. (Pubitemid 41317822)
175. D'Alessio DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck JW. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest. 1996;97(1):133-8. (Pubitemid 26021703)